HAYWARD, Calif. and Cambridge, UK (March 20, 2006) – Solexa, Inc. (NASDAQ: SLXA) today announced that it will release 2005 fourth quarter and year end financial results after market close on Tuesday, March 28, 2006.  Solexa management will host an investment-community conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss those results and answer questions.

Individuals interested in participating in the conference call may do so by dialing (877) 815-7177 for domestic callers, or (706) 679-0753 for international callers.  Those interested in listening to the conference call live via the Internet may do so by visiting the Investors section of the Company’s Web site at www.solexa.com. 

A webcast replay will be available on the Solexa Web site.  A telephone replay will be available for 48 hours following the conclusion of the call by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and entering reservation code 6410912.  

- ENDS - 

About Solexa

Solexa, Inc. is developing and preparing to commercialize the Solexa Genome Analysis System, which will be used to perform a range of analyses including whole genome resequencing, gene expression analysis and small-RNA analysis. Solexa expects its first-generation instrument, the 1G Genome Analyzer, to generate over a billion bases of DNA sequence per run and to enable whole genome resequencing below $100,000 per sample, making it the first platform to reach this important milestone. Solexa's longer-term goal is to reduce the cost of human resequencing to a few thousand dollars for use in a wide range of applications from basic research through clinical diagnostics. For further information, please visit www.solexa.com. 

This press release contains "forward-looking" statements, including statements related to the current views of Solexa management as to intellectual property matters, future products, product development and commercialization of the Company’s novel genetic analysis technology, and the expansion and success of Solexa's commercial application of its genomics technologies.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "predicts," "expects," "envisions," "hopes," "estimates," "intends," "will," "continue," "may," "potential," "should," "confident," "could" and similar expressions are intended to identify forward-looking statements. There can be no assurance that such expectations of any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. There are a number of important factors that could cause the results of Solexa to differ materially from those indicated by these forward-looking statements including, among others, risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2004, its Form 10-Q for the quarter ended September 30, 2005 and its registration statement on Form S-3 filed with the SEC on January 27, 2006. Solexa does not undertake any obligation to update forward-looking statements. 

For more information, please contact:  

Solexa, Inc.   

Linda Rubinstein, Vice President and CFO

lrubinstein@solexa.com

(510) 670-9300  

European Media Contact:

Northbank Communications

Sue Charles, CEO

+44 (0)20 7886 8152

s.charles@northbankcommunications.com  

Investor Contacts: 

Lippert/Heilshorn & Associates

Jody Cain (jcain@lhai.com)

Mariann Ohanesian (mohanesian@lhai.com)

310/691-7100